Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

casirivimab/imdevimab

A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-COVID cocktail REGN-COV2
anti-Spike SARS-CoV-2 monoclonal antibodies REGN-COV2
casirivimab and imdevimab
casirivimab plus imdevimab
casirivimab+imdevimab
REGN10933 plus REGN10987
REGN10933/REGN10987
REGN10933+REGN10987
SARS-CoV-2-specific antibodies REGN10933 and REGN10987
US brand name:REGEN-COV
Code name:REGN COV2
REGN-COV2
REGNCOV2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search